Mustang Bio Files Q1 2025 10-Q
Ticker: MBIO · Form: 10-Q · Filed: May 14, 2025 · CIK: 1680048
Sentiment: neutral
Topics: 10-Q, financials, capital-structure
Related Tickers: FBRX
TL;DR
MBIO Q1 2025 10-Q filed. Financials look stable, check capital structure.
AI Summary
Mustang Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company's financial statements show details regarding its common stock, additional paid-in capital, and retained earnings for various periods, including March 31, 2025, December 31, 2024, and March 31, 2024. The filing also references a Second Amended and Restated Founders' Agreement.
Why It Matters
This filing provides a snapshot of Mustang Bio's financial health and capital structure as of the first quarter of 2025, which is crucial for investors to assess the company's financial standing.
Risk Assessment
Risk Level: medium — As a biotech company, Mustang Bio faces inherent risks related to drug development and regulatory approvals, which are not fully detailed in this financial filing.
Key Numbers
- 0.02 — P1Y3M18D (Represents a financial metric or ratio for a specific period.)
- 0.02 — P9M18D (Represents a financial metric or ratio for a specific period.)
Key Players & Entities
- Mustang Bio, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- Fortress Biotech, Inc. (company) — Related party member
- Second Amended and Restated Founders' Agreement (document) — Referenced agreement
FAQ
What is the total amount of Additional Paid-In Capital as of March 31, 2025?
The filing indicates that Additional Paid-In Capital as of March 31, 2025, is a relevant figure, though the exact dollar amount is not explicitly stated in the provided snippet.
What was the company's Retained Earnings balance at the end of fiscal year 2024?
The filing references Retained Earnings for December 31, 2024, but the specific dollar amount is not provided in this excerpt.
Is Fortress Biotech, Inc. a majority-owned subsidiary of Mustang Bio, Inc.?
The filing notes 'mbio:FortressBiotechIncMember' and 'us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember', suggesting a relationship, but the exact nature of control is not detailed here.
What is the significance of the 'Second Amended and Restated Founders' Agreement'?
This agreement is referenced in relation to the period of January 1, 2024, to March 31, 2024, and likely pertains to the terms and conditions set forth by the company's founders.
What does the 'CommonStockIssuableMember' refer to?
This term relates to common stock that is issuable by the company, with data points provided for December 31, 2024, and December 31, 2023.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding MUSTANG BIO, INC. (MBIO).